Related Experiment Video
Updated: May 4, 2026
11:17
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
11.6K
Risk prediction for linezolid-induced thrombocytopenia and exposure-guided safety optimization
Saki Takahashi1, Yasuhiro Tsuji1
1Laboratory of Clinical Pharmacometrics, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi, Chiba, 274-8555, Japan.
Summary
Linezolid-associated thrombocytopenia can be prevented using model-informed precision dosing. Therapeutic drug monitoring and risk assessment allow for individualized Linezolid (LZD) treatment, maintaining efficacy while avoiding toxicity.
Area of Science:
- Pharmacology
- Hematology
- Infectious Diseases
Background:
- Linezolid (LZD) treatment for MRSA infections can cause thrombocytopenia (TP), a serious hematotoxicity.
- TP often necessitates treatment discontinuation, limiting LZD's utility.
- Identifying and mitigating TP risk is crucial for effective MRSA management.
Purpose of the Study:
- To explore the prevention of Linezolid-associated thrombocytopenia (TP).
- To evaluate the role of therapeutic drug monitoring (TDM) and precision dosing in mitigating TP.
- To identify key risk factors influencing LZD-induced TP.
Main Methods:
- Development of population pharmacokinetic/pharmacodynamic models.
- Application of machine learning approaches to predict TP.
- Integration of individual pharmacokinetics, risk factors, and early drug concentrations within a precision-dosing framework.
Main Results:
- Identified exposure-related risk factors (renal impairment, age, drug interactions) and exposure-independent factors (baseline platelet count, treatment duration, infection severity).
- Demonstrated that early TDM and risk stratification can predict and prevent TP.
- Showcased the effectiveness of model-informed precision dosing in maintaining LZD concentrations below toxicity thresholds.
Conclusions:
- Model-informed precision dosing is a rational and clinically applicable strategy to prevent LZD-induced TP.
- Individualized, exposure-guided therapy is superior to fixed dosing for Linezolid.
- Early TDM enables proactive dose adjustments, ensuring safe and effective LZD treatment continuation.
Related Concept Videos
01:24Drug Toxicity: Risk factors
229
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
229
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
627
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
627
01:29Therapeutic Drug Monitoring: Affecting Factors
429
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
429